Biotech Values

[DewDiligence]

AAVL—Of all the issues to pop-up out of the trial, safety isn't on my list. Subretinal injection is fine, little to go wrong with skilled personnel carrying out the vitrectomy.

I respect your knowledge of the company’s technology, but I’m not fully convinced that a safety issue can be ruled out. Inasmuch as VA improved (modestly), it seems strained to assert that the increased retinal thickness in the AVA-101 arm was surely a consequence of natural disease progression and not something more sinister. Regards, Dew